Literature DB >> 6362562

Comparison of the concentrations of ceftazidime in the serum of newborn infants after intravenous and intramuscular administration.

A Boccazzi, M Rizzo, M L Caccamo, B M Assael.   

Abstract

The concentrations of ceftazidime in serum were studied in 16 preterm and term neonates to whom a single dose of 50 mg/kg had been administered intramuscularly or intravenously. After intramuscular injection, concentrations of ceftazidime in serum were comparable to those obtained with the intravenous dose, although they were more variable. Peak serum levels ranging from 50 to 102 micrograms/ml were reached 30 to 60 min after intramuscular injection. The concentrations declined monoexponentially after the peak, with a mean half-life of 3.8 +/- 1.1 h. Concentrations of ceftazidime in serum declined biexponentially after intravenous injection, with a terminal half-life of 4.7 +/- 1.5 h.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6362562      PMCID: PMC185416          DOI: 10.1128/AAC.24.6.955

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Beta-lactamase-producing Bacteroides species in the oral cavity in relation to penicillin therapy.

Authors:  A Heimdahl; L von Konow; C E Nord
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

Review 2.  The tetracyclines: prospects at the beginning of the 1980s.

Authors:  I Chopra; T G Howe; A H Linton; K B Linton; M H Richmond; D C Speller
Journal:  J Antimicrob Chemother       Date:  1981-07       Impact factor: 5.790

3.  Antibacterial activity and beta-lactamase stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

  3 in total
  8 in total

Review 1.  [Ceftazidime in the treatment of pediatric infections--a review].

Authors:  D Adam; R Tolxdorff-Neutzling
Journal:  Infection       Date:  1987       Impact factor: 3.553

2.  Pharmacokinetics of ceftazidime in newborn infants.

Authors:  G H McCracken; N Threlkeld; M L Thomas
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibacterial drugs in neonates.

Authors:  C M Paap; M C Nahata
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

4.  Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin.

Authors:  J N van den Anker; W C Hop; R C Schoemaker; B J van der Heijden; H J Neijens; R de Groot
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

5.  Once-daily versus twice-daily administration of ceftazidime in the preterm infant.

Authors:  J N van den Anker; R C Schoemaker; B J van der Heijden; H M Broerse; H J Neijens; R de Groot
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 7.  Pharmacokinetics of cephalosporins in the neonate: a review.

Authors:  Gian Maria Pacifici
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 8.  Clinical Pharmacokinetics of Penicillins, Cephalosporins and Aminoglycosides in the Neonate: A Review.

Authors:  Gian Maria Pacifici
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.